Clinical trialNCT00820898CompletedPhase 2Interventional

Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

SponsorGynecologic Oncology GroupEnrollment24Endometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaEndometrial Clear Cell AdenocarcinomaRecurrent Uterine Corpus Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial is studying the side effects of gemcitabine and to see how well it works in treating patients with recurrent or persistent endometrial cancer. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

David Tait
Gynecologic Oncology Group
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Hartford Hospital
Hartford, Connecticut, United States
Rush University Medical Center
Chicago, Illinois, United States
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Decatur Memorial Hospital
Decatur, Illinois, United States
Memorial Medical Center
Springfield, Illinois, United States
Saint Vincent Hospital and Health Services
Indianapolis, Indiana, United States
University of Iowa/holden Comprehensive Cancer Center
Iowa City, Iowa, United States
Maine Medical Center-Bramhall Campus
Portland, Maine, United States
Cooper Hospital University Medical Center
Camden, New Jersey, United States
Carolinas Medical Center
Charlotte, North Carolina, United States
Metrohealth Medical Center
Cleveland, Ohio, United States
Riverside Methodist Hospital
Columbus, Ohio, United States
Lake University Ireland Cancer Center
Mentor, Ohio, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Tulsa Cancer Institute
Tulsa, Oklahoma, United States
Abington Memorial Hospital
Abington, Pennsylvania, United States
Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States
Women and Infants Hospital
Providence, Rhode Island, United States
Zale Lipshy University Hospital
Dallas, Texas, United States
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Gemcitabine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Feb 2009
Primary completion: 31 Jan 2011
Completion: —
Last update posted: 29 Dec 2017
Registered enrollment: 24
Registry id: NCT00820898

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.